Literature DB >> 25193670

Effects of baseline coronary occlusion and diabetes mellitus in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Raffaele Piccolo1, Gennaro Galasso1, Allan Zeeberg Iversen2, Ingo Eitel3, Alberto Dominguez-Rodriguez4, Youlan L Gu5, Bart J G L de Smet6, Karim D Mahmoud5, Pedro Abreu-Gonzalez7, Bruno Trimarco1, Holger Thiele3, Federico Piscione8.   

Abstract

Several studies have highlighted the prognostic role of preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow in the infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of preprocedural IRA occlusion in patients with diabetes with STEMI has been insufficiently studied. The aim of this study was to evaluate the effects of baseline IRA occlusion and diabetic status in patients with STEMI who underwent primary percutaneous coronary intervention by using data from a pooled analysis of randomized trials comparing intracoronary with intravenous abciximab bolus administration. A total of 3,046 patients with STEMI who underwent primary percutaneous coronary intervention were included. Diabetes was present in 578 patients (19%). The primary outcome was mortality after a median follow-up period of 375 days. Secondary end points were reinfarction and stent thrombosis. In patients without diabetes, IRA occlusion versus no occlusion was not associated with increased rates of mortality (4.3% vs 2.7%, p = 0.051) and reinfarction (3.3% vs 2.5%, p = 0.33). Patients with diabetes with IRA occlusion compared with those without occlusion showed higher rates of mortality (10.6% vs 4.6%, p = 0.01) and reinfarction (5.6% vs 2.1%, p = 0.03). Baseline IRA occlusion increased the rate of stent thrombosis in the nondiabetic (2.1% vs 1.0%, p = 0.04) and diabetic (3.2% vs 0.8%, p = 0.05) cohorts. Interaction analysis demonstrated that the risk for death and reinfarction was significantly increased when diabetes and IRA occlusion occurred concomitantly. In conclusion, patients with STEMI with diabetes and baseline IRA occlusion had disproportionately higher rates of death and reinfarction. Preprocedural IRA occlusion increased the risk for stent thrombosis, irrespective of diabetic status.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25193670     DOI: 10.1016/j.amjcard.2014.07.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.

Authors:  Sherin Bakhashab; Fahad W Ahmed; Hans-Juergen Schulten; Ayat Bashir; Sajjad Karim; Abdulrahman L Al-Malki; Mamdooh A Gari; Adel M Abuzenadah; Adeel G Chaudhary; Mohammed H Alqahtani; Sahira Lary; Farid Ahmed; Jolanta U Weaver
Journal:  Cardiovasc Diabetol       Date:  2016-02-09       Impact factor: 9.951

2.  Proangiogenic Effect of Metformin in Endothelial Cells Is via Upregulation of VEGFR1/2 and Their Signaling under Hyperglycemia-Hypoxia.

Authors:  Sherin Bakhashab; Farid Ahmed; Hans-Juergen Schulten; Fahad W Ahmed; Michael Glanville; Mohammed H Al-Qahtani; Jolanta U Weaver
Journal:  Int J Mol Sci       Date:  2018-01-19       Impact factor: 5.923

3.  Association of Monocyte Count on Admission with the Angiographic Thrombus Burden in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Zuoyan Wang; Na Liu; Lihui Ren; Licheng Lei; Huiming Ye; Jianjun Peng
Journal:  Arq Bras Cardiol       Date:  2018-03-12       Impact factor: 2.000

4.  The Spatial Distribution of Plaque Vulnerabilities in Patients with Acute Myocardial Infarction.

Authors:  Guian Zheng; Yuxin Li; Tadateru Takayama; Toshihiko Nishida; Mitsumasa Sudo; Hironori Haruta; Daisuke Fukamachi; Kimie Okubo; Yoshiharu Higuchi; Takafumi Hiro; Satoshi Saito; Atsushi Hirayama
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

5.  Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study.

Authors:  Fahad W Ahmed; Sherin Bakhashab; Inda T Bastaman; Rachel E Crossland; Michael Glanville; Jolanta U Weaver
Journal:  Int J Mol Sci       Date:  2018-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.